Impact Biomedical IBO Insider Ownership

Updated Nov 6, 2026

Over the past year, IBO insiders sold $59,522 of stock (95.91K shares) on the open market and bought none.

• Counted by insider, open-market selling of IBO stock in the past 12 months came from 3 insiders, with no insider buying.
• The largest open-market sales of IBO in the past 12 months were by Jason Grady (Director), totaling $32,505 (50K shares), most recently on March 23, 2026.
• Impact Biomedical's latest insider trade on the open market was a sale of 156 shares for $1,101 by DSS Inc. (10% owner) on September 24, 2026.
• Business Quant data puts insider holdings in IBO at 816.7K shares across insiders' latest Form 4 filings.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 6.50% (53.1K shares) of Impact Biomedical's insider total, with the other 93.50% (763.6K shares) held directly.
• Holdings in Impact Biomedical stock are reported by 5 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Impact Biomedical's three largest insider shareholders, based on their latest Form 4 filings, are DSS Inc. (10% owner, 642.62K shares), Frank D. Heuszel (Chief Executive Officer, 97.34K shares) and Melissa Kaye Sims (Director, 32.11K shares).
• Of the shares held by IBO insiders, 78.68% belong to DSS Inc.
• Institutions owned 3.56% of IBO shares as of Q2 2026; insiders' latest Form 4 filings account for about 0.76%, leaving roughly 95.68% with other investors, including the public.
• Over the trailing 12 months, 10 insiders reported transactions in IBO stock across 12 Form 4 filings.
• These insider figures for Impact Biomedical are based on Form 4 filings through November 5, 2026.